首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).
【24h】

Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs).

机译:产生广谱β-内酰胺酶(ESBLs)的革兰氏阴性细菌的多药耐药性。

获取原文
获取原文并翻译 | 示例
           

摘要

In 1983, just two years after the introduction of the oxymino-beta-lactams to the market , the first extended-spectrum beta-lactamases were isolated in Germany from Klebsiella pneumoniae strains. Since then several outbreaks have been reported in many European countries and the USA, and nowadays in several places worldwide the problem seems to reach endemic dimensions, with rates exceeding 50% in some countries, such as Portugal and Turkey. On the other hand not only K. pneumoniae but also Escherichia coli strains, with Enterobacter aerogenes predominating among the other enterobacteriaceal species, are increasingly reported as ESBL producers. In this review types, molecular characteristics, detection methods, epidemiology as well as interventions for therapy and antibiotic strategies to prevent and control infections caused by ESBL-producing microorganisms, are presented and discussed.
机译:在1983年,即将oxymino-β-内酰胺酶投放市场后仅两年,德国就从肺炎克雷伯菌中分离出了首批超广谱β-内酰胺酶。从那以后,在许多欧洲国家和美国都报告了几起暴发,如今,在世界各地的许多地方,该问题似乎已经蔓延开来,在某些国家,如葡萄牙和土耳其,其发病率已超过50%。另一方面,越来越多地报道了在其他肠杆菌种中,以肺炎克雷伯菌和大肠杆菌菌株为主要来源的是产气肠杆菌。在这篇综述中,介绍并讨论了分子特征,检测方法,流行病学以及用于预防和控制由产ESBL的微生物引起的感染的治疗干预措施和抗生素策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号